This might even be called… “the attack of the obvious”, but the bank does list out about 20 likely M&A targets for Merck — and its compatriots in Big Pharma this morning.
I note it mostly to say I concur that in terms of flexibility, Rahway is at the top of the heap, in near term deal doing.
It also has shown discipline on price, in the prior two years — coupled to a bold appetite… so, what’s not to like?
Ever onward, grinning.
नमस्ते
Powerline Lies... 